董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Jeffrey Goater | 男 | Director | 45 | 232.37万美元 | 未持股 | 2021-04-12 |
| Laurie D. Stelzer | 女 | Director | 53 | 8.75万美元 | 未持股 | 2021-04-12 |
| Armen B. Shanafelt | 男 | Director | 61 | 8.00万美元 | 未持股 | 2021-04-12 |
| Robert W. Ross | 男 | Chief Executive Officer, President and Director | 47 | 112.10万美元 | 未持股 | 2021-04-12 |
| David S. Grayzel | 男 | Director | 53 | 7.55万美元 | 未持股 | 2021-04-12 |
| Ramy Ibrahim | 男 | Director | 46 | 6.75万美元 | 未持股 | 2021-04-12 |
| Elliott Sigal | 男 | Director | 69 | 7.15万美元 | 未持股 | 2021-04-12 |
| Geoffrey McDonough | 男 | Director | 50 | 8.50万美元 | 未持股 | 2021-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert W. Ross | 男 | Chief Executive Officer, President and Director | 47 | 112.10万美元 | 未持股 | 2021-04-12 |
| Jessica Fees | 女 | Senior Vice President, Finance and Treasurer | 49 | 未披露 | 未持股 | 2021-04-12 |
| Liisa I. Nogelo | 女 | Chief Legal Officer and Secretary | 50 | 未披露 | 未持股 | 2021-04-12 |
| Wendy Dwyer | 女 | Chief Business Officer | 47 | 未披露 | 未持股 | 2021-04-12 |
| Vito J. Palombella | 男 | Chief Scientific Officer | 58 | 108.76万美元 | 未持股 | 2021-04-12 |
董事简历
中英对照 | 中文 | 英文- J. Jeffrey Goater
-
J. Jeffrey Goater，自2015年4月起担任公司财务和业务拓展高级副总裁，2013年9月-2015年4月担任业务拓展副总裁。在加入公司之前，他是Synageva BioPharma Corp. NASDAQ： GEVA的业务拓展副总裁（2013年4月-2013年7月）；在那之前，他在Evercore Partners股份有限公司（Evercore Partners, Inc.，（NYSE： EVR））担任一名投资银行家（2008年4月-2013年3月），目前担任总经理。在那之前，他担任Cowen and Company有限责任公司（Cowen and Company, LLC，（NASDAQ： COWN））的公司研究分析师，覆盖生物制药行业（2004-2008年）。他也担任Vaccinex股份有限公司（Vaccinex, Inc.）的董事会成员。他拥有生物学士学位、病理与分子医学硕士学位和微生物学与免疫学硕士学位和工商管理硕士学位，这些学位都来自罗切斯特大学（University of Rochester）。
J. Jeffrey Goater has served as the Chairman of our Board of Directors since April 2021. Mr. Goater previously served as our Chief Executive Officer and a member of our Board of Directors from February 2018 to March 2021 as our Secretary from February 2017 to September 2018 and as our Chief Business Officer from February 2017 to February 2018. Prior to Surface, Mr. Goater served as the Chief Financial Officer and held other senior business and finance positions at Voyager Therapeutics, Inc., from September 2013 to December 2016. Prior to that, he served as Vice President of Business Development at Synageva BioPharma Corp. now Alexion Pharmaceuticals, Inc., from April 2013 to July 2013 and prior to that, he worked as an investment banker at Evercore Partners Inc. (now Evercore Inc.), from April 2008 to April 2013 most recently as Managing Director. Prior to that, Mr. Goater worked as an equity research analyst at Cowen and Company, LLC, covering the biopharmaceutical sector, from August 2004 to March 2008. He also currently serves on the Board of Directors of two publicly traded biotechnology companies, Vaccinex, Inc. and LogicBio Theraputics. Mr. Goater received a B.A. in Biology, an M.S. in Pathology, an M.S. in Microbiology and Immunology, and an M.B.A., all from the University of Rochester. - J. Jeffrey Goater，自2015年4月起担任公司财务和业务拓展高级副总裁，2013年9月-2015年4月担任业务拓展副总裁。在加入公司之前，他是Synageva BioPharma Corp. NASDAQ： GEVA的业务拓展副总裁（2013年4月-2013年7月）；在那之前，他在Evercore Partners股份有限公司（Evercore Partners, Inc.，（NYSE： EVR））担任一名投资银行家（2008年4月-2013年3月），目前担任总经理。在那之前，他担任Cowen and Company有限责任公司（Cowen and Company, LLC，（NASDAQ： COWN））的公司研究分析师，覆盖生物制药行业（2004-2008年）。他也担任Vaccinex股份有限公司（Vaccinex, Inc.）的董事会成员。他拥有生物学士学位、病理与分子医学硕士学位和微生物学与免疫学硕士学位和工商管理硕士学位，这些学位都来自罗切斯特大学（University of Rochester）。
- J. Jeffrey Goater has served as the Chairman of our Board of Directors since April 2021. Mr. Goater previously served as our Chief Executive Officer and a member of our Board of Directors from February 2018 to March 2021 as our Secretary from February 2017 to September 2018 and as our Chief Business Officer from February 2017 to February 2018. Prior to Surface, Mr. Goater served as the Chief Financial Officer and held other senior business and finance positions at Voyager Therapeutics, Inc., from September 2013 to December 2016. Prior to that, he served as Vice President of Business Development at Synageva BioPharma Corp. now Alexion Pharmaceuticals, Inc., from April 2013 to July 2013 and prior to that, he worked as an investment banker at Evercore Partners Inc. (now Evercore Inc.), from April 2008 to April 2013 most recently as Managing Director. Prior to that, Mr. Goater worked as an equity research analyst at Cowen and Company, LLC, covering the biopharmaceutical sector, from August 2004 to March 2008. He also currently serves on the Board of Directors of two publicly traded biotechnology companies, Vaccinex, Inc. and LogicBio Theraputics. Mr. Goater received a B.A. in Biology, an M.S. in Pathology, an M.S. in Microbiology and Immunology, and an M.B.A., all from the University of Rochester.
- Laurie D. Stelzer
-
Laurie D. Stelzer，高级副总裁和首席财务官。Stelzer，2015年加入Halozyme担任高级副总裁、首席财务官。加入Halozyme之前，Stelzer从2004年4月到2015年1月担任Shire, Inc. 金融高级副总裁，支持研发和技术运营；在此之前她曾于2012年3月到2014年4月担任Shire的Regenerative Medicine Division分部首席财务官和投资者关系主管。加入Shire之前，Stelzer曾在Amgen, Inc.任职15年，担任多个职位，包括代理财务主管、新兴市场扩展主管、全球商业金融执行主管和全球会计主管。在她的职业生涯早期，她在房地产和银行行业担任多个金融和会计职位。Stelzer持有洛杉矶the Anderson School at the University of California工商管理硕士学位；Arizona State University会计理学学士学位。
Laurie D. Stelzer has served as a member of our Board of Directors since February 2018. She serves as Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals, Inc., which she joined in March 2020. Prior to that, she served as Senior Vice President, Chief Financial Officer at Halozyme Therapeutics, Inc. from June 2015 to March 2020. Prior to joining Halozyme, Ms. Stelzer served from April 2014 to January 2015 as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that, she was the Division Chief Financial Officer for the Regenerative Medicine Division and the Head of Investor Relations at Shire from March 2012 to April 2014. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer currently serves on the Board of Directors of PMV Pharmaceuticals. Ms. Stelzer received her M.B.A. from the UCLA Anderson School of Management, and a B.S. in Accounting from Arizona State University. - Laurie D. Stelzer，高级副总裁和首席财务官。Stelzer，2015年加入Halozyme担任高级副总裁、首席财务官。加入Halozyme之前，Stelzer从2004年4月到2015年1月担任Shire, Inc. 金融高级副总裁，支持研发和技术运营；在此之前她曾于2012年3月到2014年4月担任Shire的Regenerative Medicine Division分部首席财务官和投资者关系主管。加入Shire之前，Stelzer曾在Amgen, Inc.任职15年，担任多个职位，包括代理财务主管、新兴市场扩展主管、全球商业金融执行主管和全球会计主管。在她的职业生涯早期，她在房地产和银行行业担任多个金融和会计职位。Stelzer持有洛杉矶the Anderson School at the University of California工商管理硕士学位；Arizona State University会计理学学士学位。
- Laurie D. Stelzer has served as a member of our Board of Directors since February 2018. She serves as Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals, Inc., which she joined in March 2020. Prior to that, she served as Senior Vice President, Chief Financial Officer at Halozyme Therapeutics, Inc. from June 2015 to March 2020. Prior to joining Halozyme, Ms. Stelzer served from April 2014 to January 2015 as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc. Prior to that, she was the Division Chief Financial Officer for the Regenerative Medicine Division and the Head of Investor Relations at Shire from March 2012 to April 2014. Prior to Shire, Ms. Stelzer held positions of increasing responsibility for 15 years at Amgen, Inc., including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. Early in her career, she held various finance and accounting positions in the real estate and banking industries. Ms. Stelzer currently serves on the Board of Directors of PMV Pharmaceuticals. Ms. Stelzer received her M.B.A. from the UCLA Anderson School of Management, and a B.S. in Accounting from Arizona State University.
- Armen B. Shanafelt
-
Armen B. Shanafelt， 博士-2010年1月起担任我们董事会成员。2009年4月来，Shanafelt博士一直是风险投资公司Lilly Ventures合作伙伴。加入Lilly Ventures之前，Shanafelt博士是医药研究公司，包括肿瘤学的治疗领域，内分泌和神经科学，Eli Lilly 和本公司，首席科学官负责早期的生长。Shanafelt博士目前担任上市生物科技公司Aeglea BioTherapeutics, Inc.董事会主席，并作为以下私营生物技术公司董事：Aileron Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Bio Chairman。Shanafelt博士获得了 Pacific Lutheran University化学和物理学学士学位，和加州大学的化学博士学位。他在DNAX研究所完成了他的博士后工作，在那里他学习了细胞因子及其受体的结构关系。
Armen B. Shanafelt has served as a member of our Board of Directors since November 2014. He has been investing in leading biotech companies since April 2009 as a member of Lilly Ventures Fund I, LLC. Prior to that, Dr. Shanafelt served as the Chief Scientific Officer of Biotherapeutics Lead Generation at Eli Lilly and Company from January 2002 to April 2009. Prior to joining Eli Lilly, he was a Research Fellow and Director of Drug Monitoring Research at Roche Diagnostics Corporation, a global diagnostics company, from 2000 to 2002 and held several leadership positions in the Biotechnology Division at Bayer Corporation, a multinational chemical and healthcare corporation from 1993 to 2000. In addition to Surface Oncology, Dr. Shanafelt currently serves on the Board of Directors of Aeglea BioTherapeutics, a publicly traded biopharmaceutical company. Dr. Shanafelt received a B.S. in Chemistry and Physics from Pacific Lutheran University and a Ph.D. in Chemistry from the University of California, Berkeley. - Armen B. Shanafelt， 博士-2010年1月起担任我们董事会成员。2009年4月来，Shanafelt博士一直是风险投资公司Lilly Ventures合作伙伴。加入Lilly Ventures之前，Shanafelt博士是医药研究公司，包括肿瘤学的治疗领域，内分泌和神经科学，Eli Lilly 和本公司，首席科学官负责早期的生长。Shanafelt博士目前担任上市生物科技公司Aeglea BioTherapeutics, Inc.董事会主席，并作为以下私营生物技术公司董事：Aileron Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Bio Chairman。Shanafelt博士获得了 Pacific Lutheran University化学和物理学学士学位，和加州大学的化学博士学位。他在DNAX研究所完成了他的博士后工作，在那里他学习了细胞因子及其受体的结构关系。
- Armen B. Shanafelt has served as a member of our Board of Directors since November 2014. He has been investing in leading biotech companies since April 2009 as a member of Lilly Ventures Fund I, LLC. Prior to that, Dr. Shanafelt served as the Chief Scientific Officer of Biotherapeutics Lead Generation at Eli Lilly and Company from January 2002 to April 2009. Prior to joining Eli Lilly, he was a Research Fellow and Director of Drug Monitoring Research at Roche Diagnostics Corporation, a global diagnostics company, from 2000 to 2002 and held several leadership positions in the Biotechnology Division at Bayer Corporation, a multinational chemical and healthcare corporation from 1993 to 2000. In addition to Surface Oncology, Dr. Shanafelt currently serves on the Board of Directors of Aeglea BioTherapeutics, a publicly traded biopharmaceutical company. Dr. Shanafelt received a B.S. in Chemistry and Physics from Pacific Lutheran University and a Ph.D. in Chemistry from the University of California, Berkeley.
- Robert W. Ross
-
RobertW.Ross自2016年10月起担任我们的首席医疗官。在加入Surface之前，罗斯博士于2015年10月至2016年10月担任bluebirdbio，Inc.肿瘤学主管，2015年1月至2016年10月担任临床开发和药物警戒高级副总裁，2012年10月至2015年1月担任临床开发Vice President。在此之前，他曾于2007年10月至2012年10月在InfinityPharmaceuticals，Inc.工作。Ross博士于2003年7月至2007年8月担任Dana Farber Cancer Center的医学肿瘤学研究员和教员，然后于2007年8月至2015年10月在Dana Farber Cancer维持临床实践。Ross博士在斯坦福大学（Stanford University）获得生物科学学士学位和哲学学士学位，在哈佛医学院（Harvard Medical School）的临床研究人员培训计划中获得医学硕士学位，并在哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位。他在加州大学旧金山分校（University of California，San Francisco）完成内科住院医师培训。
Robert W. Ross has served as our Chief Executive Officer and member of our Board of Directors since April 2021. Dr. Ross previously served as our Chief Medical Officer from October 2016 to March 2021. Prior to Surface, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016 Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016 and Vice President of Clinical Development, from October 2012 to January 2015. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute from July 2003 to August 2007 and then maintained a clinical practice at Dana Farber Cancer Institute from August 2007 to October 2015. Dr. Ross currently serves on the Board of Directors of Obsidian Therapeutics, a biotechnology company. Dr. Ross received a B.S. in Biological Sciences and a BA in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco. - RobertW.Ross自2016年10月起担任我们的首席医疗官。在加入Surface之前，罗斯博士于2015年10月至2016年10月担任bluebirdbio，Inc.肿瘤学主管，2015年1月至2016年10月担任临床开发和药物警戒高级副总裁，2012年10月至2015年1月担任临床开发Vice President。在此之前，他曾于2007年10月至2012年10月在InfinityPharmaceuticals，Inc.工作。Ross博士于2003年7月至2007年8月担任Dana Farber Cancer Center的医学肿瘤学研究员和教员，然后于2007年8月至2015年10月在Dana Farber Cancer维持临床实践。Ross博士在斯坦福大学（Stanford University）获得生物科学学士学位和哲学学士学位，在哈佛医学院（Harvard Medical School）的临床研究人员培训计划中获得医学硕士学位，并在哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位。他在加州大学旧金山分校（University of California，San Francisco）完成内科住院医师培训。
- Robert W. Ross has served as our Chief Executive Officer and member of our Board of Directors since April 2021. Dr. Ross previously served as our Chief Medical Officer from October 2016 to March 2021. Prior to Surface, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016 Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016 and Vice President of Clinical Development, from October 2012 to January 2015. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute from July 2003 to August 2007 and then maintained a clinical practice at Dana Farber Cancer Institute from August 2007 to October 2015. Dr. Ross currently serves on the Board of Directors of Obsidian Therapeutics, a biotechnology company. Dr. Ross received a B.S. in Biological Sciences and a BA in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco.
- David S. Grayzel
-
DavidS.Grayzel是我们的联合创始人，自2014年4月以来一直担任我们的董事会成员。Grayzel博士还于2014年4月至2015年5月担任我们的首席执行官，并于2014年4月至2017年1月担任我们的董事会主席。Grayzel博士自2014年4月起担任Atlas Venture Inc.的合伙人。自2010年6月加入Atlas Venture Inc.担任董事总经理以来，Grayzel博士共同创立并担任Arteaus Therapeutics的首席执行官，LLC从2011年6月到2014年1月被礼来公司收购，从2011年5月到2015年2月被The Medicines Company收购，担任Annovation Biopharma，Inc.的联合创始人兼首席执行官。他是Cadent Therapeutics，Inc.（现为Luc Therapeutics，Inc.）的联合创始人和董事会成员，2015年9月至2017年1月被新基医药公司收购，他是Delinia，Inc.的创始董事会成员，也是Quartet Medicine的联合创始人和董事会观察员，Inc.自2013年12月起。在此之前，他于2002年8月至2010年6月担任InfinityPharmaceuticals，Inc.临床开发和医疗事务Vice President。Grayzel博士任职于Acera School，Inc.的董事会。马萨诸塞科学、创造力和领导力学院。Grayzel博士还担任纪念斯隆·凯特琳癌症中心（Memorial Sloan Kettering Cancer Center&8217；s Technology Development Fund）的顾问和三机构疗法发现研究所（Tri-Institutional Therapeutics Discovery Institute）的科学顾问委员会成员。Grayzel博士在斯坦福大学（Stanford University）获得心理学学士学位，在哈佛医学院（Harvard Medical School）获得医学硕士学位，并在马萨诸塞州总医院（Massachusetts General Hospital）完成内科实习和住院医师培训。
David S. Grayzel is our co-founder and has served as a member of our Board of Directors since April 2014. Dr. Grayzel has also served as our Chief Executive Officer from April 2014 to May 2015 and Chairman of our Board of Directors from April 2014 to January 2017. Dr. Grayzel has been a Partner at Atlas Venture Inc. since April 2014. Since joining Atlas Venture Inc. as a Managing Director in June 2010 Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014 and served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015. He is a co-founder and member of the Board of Directors of Cadent Therapeutics, Inc. acquired by Novartis in 2020 a founding board member of Delinia, Inc. from September 2015 until it was acquired by Celgene Corporation in January 2017 and a board member of Affinia Therapeutics, ANP Therapeutics, Aerovate Therapeutics, Xilio Therapeutics, and Q23 Bio, and is a board observer at Day One Biopharmaceuticals. Prior to that, he was Vice President of Clinical Development and Medical Affairs at Infinity Pharmaceuticals, Inc. from August 2002 to June 2010. Dr. Grayzel serves on the board of Acera School, Inc. (The Massachusetts School for Science, Creativity, and Leadership). Dr. Grayzel also serves as an advisor to Memorial Sloan Kettering Cancer Center’s Technology Development Fund and a scientific advisory board member of the Tri-Institutional Therapeutics Discovery Institute. Dr. Grayzel received a B.A. in Psychology from Stanford University and an M.D. from Harvard Medical School and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. - DavidS.Grayzel是我们的联合创始人，自2014年4月以来一直担任我们的董事会成员。Grayzel博士还于2014年4月至2015年5月担任我们的首席执行官，并于2014年4月至2017年1月担任我们的董事会主席。Grayzel博士自2014年4月起担任Atlas Venture Inc.的合伙人。自2010年6月加入Atlas Venture Inc.担任董事总经理以来，Grayzel博士共同创立并担任Arteaus Therapeutics的首席执行官，LLC从2011年6月到2014年1月被礼来公司收购，从2011年5月到2015年2月被The Medicines Company收购，担任Annovation Biopharma，Inc.的联合创始人兼首席执行官。他是Cadent Therapeutics，Inc.（现为Luc Therapeutics，Inc.）的联合创始人和董事会成员，2015年9月至2017年1月被新基医药公司收购，他是Delinia，Inc.的创始董事会成员，也是Quartet Medicine的联合创始人和董事会观察员，Inc.自2013年12月起。在此之前，他于2002年8月至2010年6月担任InfinityPharmaceuticals，Inc.临床开发和医疗事务Vice President。Grayzel博士任职于Acera School，Inc.的董事会。马萨诸塞科学、创造力和领导力学院。Grayzel博士还担任纪念斯隆·凯特琳癌症中心（Memorial Sloan Kettering Cancer Center&8217；s Technology Development Fund）的顾问和三机构疗法发现研究所（Tri-Institutional Therapeutics Discovery Institute）的科学顾问委员会成员。Grayzel博士在斯坦福大学（Stanford University）获得心理学学士学位，在哈佛医学院（Harvard Medical School）获得医学硕士学位，并在马萨诸塞州总医院（Massachusetts General Hospital）完成内科实习和住院医师培训。
- David S. Grayzel is our co-founder and has served as a member of our Board of Directors since April 2014. Dr. Grayzel has also served as our Chief Executive Officer from April 2014 to May 2015 and Chairman of our Board of Directors from April 2014 to January 2017. Dr. Grayzel has been a Partner at Atlas Venture Inc. since April 2014. Since joining Atlas Venture Inc. as a Managing Director in June 2010 Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014 and served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015. He is a co-founder and member of the Board of Directors of Cadent Therapeutics, Inc. acquired by Novartis in 2020 a founding board member of Delinia, Inc. from September 2015 until it was acquired by Celgene Corporation in January 2017 and a board member of Affinia Therapeutics, ANP Therapeutics, Aerovate Therapeutics, Xilio Therapeutics, and Q23 Bio, and is a board observer at Day One Biopharmaceuticals. Prior to that, he was Vice President of Clinical Development and Medical Affairs at Infinity Pharmaceuticals, Inc. from August 2002 to June 2010. Dr. Grayzel serves on the board of Acera School, Inc. (The Massachusetts School for Science, Creativity, and Leadership). Dr. Grayzel also serves as an advisor to Memorial Sloan Kettering Cancer Center’s Technology Development Fund and a scientific advisory board member of the Tri-Institutional Therapeutics Discovery Institute. Dr. Grayzel received a B.A. in Psychology from Stanford University and an M.D. from Harvard Medical School and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital.
- Ramy Ibrahim
-
Ramy Ibrahim自2019年9月以来一直担任我们的董事会成员。他目前担任BIT.BIO和Galaxy Way Advisors，Inc.的首席医疗官。Ibrahim博士还担任bluebirdbio，Inc.的董事会成员。他此前曾担任Parker Institute for Cancer Immunotherapy的首席医疗官兼临床开发副总裁（2016年7月至2021年1月）。加入帕克癌症免疫疗法研究所（Parker Institute for Cancer Immunotherapy）之前，他曾担任AstraZeneca PLC的免疫肿瘤学临床开发副总裁（2014年2月至2016年7月）。在此之前，他于2011年4月至2014年2月担任MedImmune，LLC临床开发肿瘤学高级医学总监。从2005年10月到2011年4月，Ibrahim博士还担任百时美施贵宝公司肿瘤学全球临床研究的集团总监。Ibrahim博士积极参与全球癌症免疫疗法网络，例如癌症免疫疗法学会SITC和ASCO。Ibrahim博士在开罗大学学习医学和医学肿瘤学，然后在马里兰州贝塞斯达的国家癌症研究所癌症疫苗分部进行临床免疫疗法研究。
Ramy Ibrahim,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation, Dr. Ibrahim served on the board of directors of bluebird bio. Dr. Ibrahim is a medical oncologist who has served as the Chief Medical Officer of CMO Milkyway Advisors since January 2021. Dr. Ibrahim also serves as a board member for Surface Oncology, Inc., as well as The Parker Institute for Cancer Immunotherapy, is a scientific advisory board member for Harpoon Therapeutics, and is a consultant for Georgiamune, LLC. Previously, he served as the Chief Medical Officer of BitBio from October 2020 to June 2022. Prior to BitBio, he served as Chief Medical Officer at the Parker Institute for Cancer Immunotherapy from 2016 to 2021. Prior to the Parker Institute, Dr. Ibrahim served as the vice president of clinical development for immuno-oncology at AstraZeneca from 2011 to 2016. In this role, he led the development of the early checkpoint inhibitor antibodies durvalumab and tremelimumab. From 2005 to 2011, at Bristol-Myers Squibb, Dr. Ibrahim played a key role in the clinical development of ipilimumab, the first FDA-approved immune checkpoint inhibitor, from early phase II through multiple global launches. He also played a key role in the early development of nivolumab, as well as the development of anti-PD-L1 and anti-CD137 antibody programs. Dr. Ibrahim trained in medicine and medical oncology at Cairo University then conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, Maryland, prior to moving into industry. - Ramy Ibrahim自2019年9月以来一直担任我们的董事会成员。他目前担任BIT.BIO和Galaxy Way Advisors，Inc.的首席医疗官。Ibrahim博士还担任bluebirdbio，Inc.的董事会成员。他此前曾担任Parker Institute for Cancer Immunotherapy的首席医疗官兼临床开发副总裁（2016年7月至2021年1月）。加入帕克癌症免疫疗法研究所（Parker Institute for Cancer Immunotherapy）之前，他曾担任AstraZeneca PLC的免疫肿瘤学临床开发副总裁（2014年2月至2016年7月）。在此之前，他于2011年4月至2014年2月担任MedImmune，LLC临床开发肿瘤学高级医学总监。从2005年10月到2011年4月，Ibrahim博士还担任百时美施贵宝公司肿瘤学全球临床研究的集团总监。Ibrahim博士积极参与全球癌症免疫疗法网络，例如癌症免疫疗法学会SITC和ASCO。Ibrahim博士在开罗大学学习医学和医学肿瘤学，然后在马里兰州贝塞斯达的国家癌症研究所癌症疫苗分部进行临床免疫疗法研究。
- Ramy Ibrahim,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation, Dr. Ibrahim served on the board of directors of bluebird bio. Dr. Ibrahim is a medical oncologist who has served as the Chief Medical Officer of CMO Milkyway Advisors since January 2021. Dr. Ibrahim also serves as a board member for Surface Oncology, Inc., as well as The Parker Institute for Cancer Immunotherapy, is a scientific advisory board member for Harpoon Therapeutics, and is a consultant for Georgiamune, LLC. Previously, he served as the Chief Medical Officer of BitBio from October 2020 to June 2022. Prior to BitBio, he served as Chief Medical Officer at the Parker Institute for Cancer Immunotherapy from 2016 to 2021. Prior to the Parker Institute, Dr. Ibrahim served as the vice president of clinical development for immuno-oncology at AstraZeneca from 2011 to 2016. In this role, he led the development of the early checkpoint inhibitor antibodies durvalumab and tremelimumab. From 2005 to 2011, at Bristol-Myers Squibb, Dr. Ibrahim played a key role in the clinical development of ipilimumab, the first FDA-approved immune checkpoint inhibitor, from early phase II through multiple global launches. He also played a key role in the early development of nivolumab, as well as the development of anti-PD-L1 and anti-CD137 antibody programs. Dr. Ibrahim trained in medicine and medical oncology at Cairo University then conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, Maryland, prior to moving into industry.
- Elliott Sigal
-
Elliott Sigal，是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS，并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事，直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问，是各种生物技术公司顾问。此外，他担任Spark Therapeutics公司的董事，也担任民间非营利基金会，黑色素瘤研究联盟的董事会成员。
Elliott Sigal has served as a member of our Board of Directors since February 2018. Dr. Sigal is a former Executive Vice President and member of the Board of Directors of Bristol-Myers Squibb, or BMS. He joined BMS in 1997 as head of Applied Genomics, went on to head Discovery Research followed by Clinical Development and ultimately served as Chief Scientific Officer and President of R&D from 2004 until 2013. Dr. Sigal serves on the Board of Directors for Adaptimmune Therapeutics plc, VIR Biotechnology, Affinia Therapeutics and the Melanoma Research Alliance. He also serves as a senior advisor to the healthcare team of New Enterprise Associates and consults for several biotechnology companies. Dr. Sigal holds an M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco, where he was on faculty from 1988 to 1992. He also holds a B.S., M.S, and Ph.D. in Engineering from Purdue University. - Elliott Sigal，是百时美施贵宝公司的前执行副总裁兼董事。他于1997年加入BMS，并在研究和发展领域担任有越来越多的责任的工作。他自2004年至2013年退休担任BMS首席研发官和研发总裁。他担任于2011年BMS董事，直到2013年退休。他曾从2002年到2011年担任普林斯顿医疗系统委员会委员。他目前担任新企业协会高级顾问的企业集团医疗团队顾问，是各种生物技术公司顾问。此外，他担任Spark Therapeutics公司的董事，也担任民间非营利基金会，黑色素瘤研究联盟的董事会成员。
- Elliott Sigal has served as a member of our Board of Directors since February 2018. Dr. Sigal is a former Executive Vice President and member of the Board of Directors of Bristol-Myers Squibb, or BMS. He joined BMS in 1997 as head of Applied Genomics, went on to head Discovery Research followed by Clinical Development and ultimately served as Chief Scientific Officer and President of R&D from 2004 until 2013. Dr. Sigal serves on the Board of Directors for Adaptimmune Therapeutics plc, VIR Biotechnology, Affinia Therapeutics and the Melanoma Research Alliance. He also serves as a senior advisor to the healthcare team of New Enterprise Associates and consults for several biotechnology companies. Dr. Sigal holds an M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco, where he was on faculty from 1988 to 1992. He also holds a B.S., M.S, and Ph.D. in Engineering from Purdue University.
- Geoffrey McDonough
-
Geoffrey McDonough，2012年11月起，担任本公司董事。2011年8月起，他担任Swedish Orphan Biovitrum AB Sobi的总裁、首席执行官，这是瑞典的制药公司。加入Sobi之前，2002年至2011年6月，他在Genzyme Corporation担任过一些高级领导职务，包括：高级副总裁、个性化优生保健总经理、溶酶体贮积症治疗高级副总裁，最后的职务是欧洲、中东与非洲地区总裁。加入Genzyme之前，他参与创办了Catalyst Medical Solutions，并曾担任其总裁，这是一个医院管理软件开发商；还曾是内科和儿科的执业医生。他在University of North Carolina at Chapel Hill获得了文科学士学位和理科学士学位，在Harvard Medical School获得医学博士学位。
Geoffrey McDonough has served as a member of our Board of Directors since February 2018. Dr. McDonough currently serves as the President, Chief Executive Officer and member of the Board of Directors of Generation Bio Co., which he joined in October 2017. He formerly served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB Sobi from August 2011 to June 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including President of Genzyme Europe and Senior Vice President and General Manager of the global lysosomal storage disease business. Dr. McDonough has a B.S. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill. He obtained his M.D. at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children’s Hospital. - Geoffrey McDonough，2012年11月起，担任本公司董事。2011年8月起，他担任Swedish Orphan Biovitrum AB Sobi的总裁、首席执行官，这是瑞典的制药公司。加入Sobi之前，2002年至2011年6月，他在Genzyme Corporation担任过一些高级领导职务，包括：高级副总裁、个性化优生保健总经理、溶酶体贮积症治疗高级副总裁，最后的职务是欧洲、中东与非洲地区总裁。加入Genzyme之前，他参与创办了Catalyst Medical Solutions，并曾担任其总裁，这是一个医院管理软件开发商；还曾是内科和儿科的执业医生。他在University of North Carolina at Chapel Hill获得了文科学士学位和理科学士学位，在Harvard Medical School获得医学博士学位。
- Geoffrey McDonough has served as a member of our Board of Directors since February 2018. Dr. McDonough currently serves as the President, Chief Executive Officer and member of the Board of Directors of Generation Bio Co., which he joined in October 2017. He formerly served as President and Chief Executive Officer of Swedish Orphan Biovitrum AB Sobi from August 2011 to June 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including President of Genzyme Europe and Senior Vice President and General Manager of the global lysosomal storage disease business. Dr. McDonough has a B.S. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill. He obtained his M.D. at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children’s Hospital.
高管简历
中英对照 | 中文 | 英文- Robert W. Ross
RobertW.Ross自2016年10月起担任我们的首席医疗官。在加入Surface之前，罗斯博士于2015年10月至2016年10月担任bluebirdbio，Inc.肿瘤学主管，2015年1月至2016年10月担任临床开发和药物警戒高级副总裁，2012年10月至2015年1月担任临床开发Vice President。在此之前，他曾于2007年10月至2012年10月在InfinityPharmaceuticals，Inc.工作。Ross博士于2003年7月至2007年8月担任Dana Farber Cancer Center的医学肿瘤学研究员和教员，然后于2007年8月至2015年10月在Dana Farber Cancer维持临床实践。Ross博士在斯坦福大学（Stanford University）获得生物科学学士学位和哲学学士学位，在哈佛医学院（Harvard Medical School）的临床研究人员培训计划中获得医学硕士学位，并在哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位。他在加州大学旧金山分校（University of California，San Francisco）完成内科住院医师培训。
Robert W. Ross has served as our Chief Executive Officer and member of our Board of Directors since April 2021. Dr. Ross previously served as our Chief Medical Officer from October 2016 to March 2021. Prior to Surface, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016 Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016 and Vice President of Clinical Development, from October 2012 to January 2015. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute from July 2003 to August 2007 and then maintained a clinical practice at Dana Farber Cancer Institute from August 2007 to October 2015. Dr. Ross currently serves on the Board of Directors of Obsidian Therapeutics, a biotechnology company. Dr. Ross received a B.S. in Biological Sciences and a BA in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco.- RobertW.Ross自2016年10月起担任我们的首席医疗官。在加入Surface之前，罗斯博士于2015年10月至2016年10月担任bluebirdbio，Inc.肿瘤学主管，2015年1月至2016年10月担任临床开发和药物警戒高级副总裁，2012年10月至2015年1月担任临床开发Vice President。在此之前，他曾于2007年10月至2012年10月在InfinityPharmaceuticals，Inc.工作。Ross博士于2003年7月至2007年8月担任Dana Farber Cancer Center的医学肿瘤学研究员和教员，然后于2007年8月至2015年10月在Dana Farber Cancer维持临床实践。Ross博士在斯坦福大学（Stanford University）获得生物科学学士学位和哲学学士学位，在哈佛医学院（Harvard Medical School）的临床研究人员培训计划中获得医学硕士学位，并在哥伦比亚大学内科医生和外科医生学院（Columbia University College of Physicians and Surgeons）获得医学博士学位。他在加州大学旧金山分校（University of California，San Francisco）完成内科住院医师培训。
- Robert W. Ross has served as our Chief Executive Officer and member of our Board of Directors since April 2021. Dr. Ross previously served as our Chief Medical Officer from October 2016 to March 2021. Prior to Surface, Dr. Ross served as Head of Oncology at bluebird bio, Inc. from October 2015 to October 2016 Senior Vice President of Clinical Development and Pharmacovigilance, from January 2015 to October 2016 and Vice President of Clinical Development, from October 2012 to January 2015. Prior to that, he worked at Infinity Pharmaceuticals, Inc. from October 2007 to October 2012. Dr. Ross was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute from July 2003 to August 2007 and then maintained a clinical practice at Dana Farber Cancer Institute from August 2007 to October 2015. Dr. Ross currently serves on the Board of Directors of Obsidian Therapeutics, a biotechnology company. Dr. Ross received a B.S. in Biological Sciences and a BA in Philosophy from Stanford University, an M.S. in Medical Science as part of the Clinical Investigator Training Program from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco.
- Jessica Fees
Jessica Fees自2018年12月起担任我们的首席财务官兼首席会计官，自2018年11月起担任财务高级副总裁。费斯女士于2015年9月加入公司，担任公司财务总监。在加入Surface之前，费斯女士于2011年1月至2016年3月担任Glide Associates LLC的总裁。在此之前，她于2005年8月至2011年6月在Tokai Pharmaceuticals，Inc.工作。费女士的职业生涯始于Arthur Andersen LLP。费斯女士拥有圣十字学院的学士学位，并在马萨诸塞州获得了注册会计师资格。
Jessica Fees has served as our principal financial officer and principal accounting officer since December 2018 and as Senior Vice President, Finance since November 2018. Ms. Fees joined the Company in September 2015 as the Company’s Director of Finance. Prior to Surface, Ms. Fees served as President of Glide Associates LLC from January 2011 to March 2016. Prior to that, she worked at Tokai Pharmaceuticals, Inc. from August 2005 to June 2011. Ms. Fees began her career at Arthur Andersen LLP. Ms. Fees has a B.A. from The College of the Holy Cross and earned her CPA in Massachusetts.- Jessica Fees自2018年12月起担任我们的首席财务官兼首席会计官，自2018年11月起担任财务高级副总裁。费斯女士于2015年9月加入公司，担任公司财务总监。在加入Surface之前，费斯女士于2011年1月至2016年3月担任Glide Associates LLC的总裁。在此之前，她于2005年8月至2011年6月在Tokai Pharmaceuticals，Inc.工作。费女士的职业生涯始于Arthur Andersen LLP。费斯女士拥有圣十字学院的学士学位，并在马萨诸塞州获得了注册会计师资格。
- Jessica Fees has served as our principal financial officer and principal accounting officer since December 2018 and as Senior Vice President, Finance since November 2018. Ms. Fees joined the Company in September 2015 as the Company’s Director of Finance. Prior to Surface, Ms. Fees served as President of Glide Associates LLC from January 2011 to March 2016. Prior to that, she worked at Tokai Pharmaceuticals, Inc. from August 2005 to June 2011. Ms. Fees began her career at Arthur Andersen LLP. Ms. Fees has a B.A. from The College of the Holy Cross and earned her CPA in Massachusetts.
- Liisa I. Nogelo
Liisa I.Nogelo自2020年1月起担任我们的首席法律官。在此之前，她于2018年7月至2020年1月担任我们的总法律顾问。在加入Surface之前，Nogelo女士于2014年8月至2018年7月领导了麻省理工学院和哈佛大学的法律团队，最近担任运营总法律顾问。加入Broad Institute之前，2007年9月至2014年7月，Nogelo女士在Biogen Idec Inc.（现为BiogenInc.）的公司和研发法律团队担任高级职位，她最近担任助理总法律顾问，并担任肌萎缩性侧索硬化（ALS）和血友病三个后期药物开发计划的首席律师。Nogelo女士获得了韦尔斯利学院的学士学位和加利福尼亚大学洛杉矶分校法学院的法学博士学位。
Liisa I. Nogelo has served as our Chief Legal Officer since January 2020. Prior to that she served as our General Counsel from July 2018 to January 2020. Prior to Surface, from August 2014 to July 2018 Ms. Nogelo led the legal team at the Broad Institute of MIT and Harvard, where she most recently served as the General Counsel, Operations. Prior to the Broad Institute, from September 2007 to July 2014 Ms. Nogelo held senior positions on both the corporate and R&D legal teams at Biogen Idec Inc. now Biogen Inc., where she most recently served as Associate General Counsel and was the lead attorney for three late-stage drug development programs in amyotrophic lateral sclerosis (ALS) and hemophilia. Ms. Nogelo earned B.A. from Wellesley College and a J.D. from the UCLA School of Law.- Liisa I.Nogelo自2020年1月起担任我们的首席法律官。在此之前，她于2018年7月至2020年1月担任我们的总法律顾问。在加入Surface之前，Nogelo女士于2014年8月至2018年7月领导了麻省理工学院和哈佛大学的法律团队，最近担任运营总法律顾问。加入Broad Institute之前，2007年9月至2014年7月，Nogelo女士在Biogen Idec Inc.（现为BiogenInc.）的公司和研发法律团队担任高级职位，她最近担任助理总法律顾问，并担任肌萎缩性侧索硬化（ALS）和血友病三个后期药物开发计划的首席律师。Nogelo女士获得了韦尔斯利学院的学士学位和加利福尼亚大学洛杉矶分校法学院的法学博士学位。
- Liisa I. Nogelo has served as our Chief Legal Officer since January 2020. Prior to that she served as our General Counsel from July 2018 to January 2020. Prior to Surface, from August 2014 to July 2018 Ms. Nogelo led the legal team at the Broad Institute of MIT and Harvard, where she most recently served as the General Counsel, Operations. Prior to the Broad Institute, from September 2007 to July 2014 Ms. Nogelo held senior positions on both the corporate and R&D legal teams at Biogen Idec Inc. now Biogen Inc., where she most recently served as Associate General Counsel and was the lead attorney for three late-stage drug development programs in amyotrophic lateral sclerosis (ALS) and hemophilia. Ms. Nogelo earned B.A. from Wellesley College and a J.D. from the UCLA School of Law.
- Wendy Dwyer
Wendy Dwyer自2019年4月起担任我们的首席商务官。在加入Surface之前，Dwyer女士于2017年7月至2019年3月担任Portal Instruments的首席商务官。在此之前，Dwyer女士于2014年7月至2017年1月担任Ipsen Bioscience企业业务发展副总裁，于2011年11月至2014年7月担任阿斯利康业务发展总监，并在Endo Pharmaceuticals（前身为Indevus Pharmaceuticals）担任高级职位，从1998年9月到2010年1月，最近担任业务开发副总裁。Dwyer女士获得了莱斯利大学的管理学硕士学位和恩迪科特学院的心理学学士学位。
Wendy Dwyer has served as our Chief Business Officer since April 2019. Prior to Surface, Ms. Dwyer served as Chief Business Officer at Portal Instruments from July 2017 to March 2019. Prior to that, Ms. Dwyer served as the Vice President of Corporate Business Development at Ipsen BioScience from July 2014 to January 2017 Business Development Director at AstraZeneca from November 2011 to July 2014 and held senior positions at Endo Pharmaceuticals formerly Indevus Pharmaceuticals, from September 1998 to January 2010 most recently as Vice President of Business Development. Ms. Dwyer received her M.S. in Management from Lesley University and her B.S. in Psychology from Endicott College.- Wendy Dwyer自2019年4月起担任我们的首席商务官。在加入Surface之前，Dwyer女士于2017年7月至2019年3月担任Portal Instruments的首席商务官。在此之前，Dwyer女士于2014年7月至2017年1月担任Ipsen Bioscience企业业务发展副总裁，于2011年11月至2014年7月担任阿斯利康业务发展总监，并在Endo Pharmaceuticals（前身为Indevus Pharmaceuticals）担任高级职位，从1998年9月到2010年1月，最近担任业务开发副总裁。Dwyer女士获得了莱斯利大学的管理学硕士学位和恩迪科特学院的心理学学士学位。
- Wendy Dwyer has served as our Chief Business Officer since April 2019. Prior to Surface, Ms. Dwyer served as Chief Business Officer at Portal Instruments from July 2017 to March 2019. Prior to that, Ms. Dwyer served as the Vice President of Corporate Business Development at Ipsen BioScience from July 2014 to January 2017 Business Development Director at AstraZeneca from November 2011 to July 2014 and held senior positions at Endo Pharmaceuticals formerly Indevus Pharmaceuticals, from September 1998 to January 2010 most recently as Vice President of Business Development. Ms. Dwyer received her M.S. in Management from Lesley University and her B.S. in Psychology from Endicott College.
- Vito J. Palombella
2010年5月以来，Vito J. Palombella担任我们的首席科学官。他负责我们的药物发现和临床前期的开发活动。担任首席科学官之前，从2006年9月至2010年5月，他担任副总裁，负责药物发现。从2004年1月至2006年9月，他担任IPI生物副总裁。加入Infinity公司之前，他担任Syntonix Pharmaceuticals分子生物学和蛋白质化学的董事，负责改善和扩大其核心Fc receptor-mediated的药物输送技术。在加入Syntonix之前，他担任Millennium Pharmaceuticals细胞和分子生物学的高级董事。1999年，通过LeukoSite的收购，他担任相同职位。在被LeukoSite收购之前，从1994年到1999年，他在ProScript公司担任一些职位。在ProScript，LeukoSite and Millennium公司工作期间，他参与Velcade bortezomib的研发，一种癌症治疗的蛋白酶体抑制剂。他还管理其他多个项目，包括研究NF-kB的监管。他拥有罗格斯大学的微生物学学士学位和纽约大学医学中心病毒性肿瘤学和免疫学的硕士和博士学位。他还是哈佛大学Tom Maniatis。博士实验室的博士后研究员。
Vito J. Palombella has served as our Chief Scientific Officer since January 2016. Prior to Surface, Dr. Palombella served in a variety of roles at Infinity Pharmaceuticals, Inc. from January 2004 to January 2016 most recently as Chief Scientific Officer. Prior to that, he was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Inc. now Biogen Inc. from October 2000 to January 2004 Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Co. Ltd.) from December 1999 to October 2000 Senior Director of Cell and Molecular Biology at LeukoSite, Inc. from July 1999 to December 1999 and held a number of positions at ProScript, Inc. from September 1994 to July 1999. Dr. Palombella currently serves on the Board of Directors of Molecular Partners AG. Dr. Palombella received a B.S. in Microbiology from Rutgers University and an M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center and completed his post-doctoral training at Harvard University.- 2010年5月以来，Vito J. Palombella担任我们的首席科学官。他负责我们的药物发现和临床前期的开发活动。担任首席科学官之前，从2006年9月至2010年5月，他担任副总裁，负责药物发现。从2004年1月至2006年9月，他担任IPI生物副总裁。加入Infinity公司之前，他担任Syntonix Pharmaceuticals分子生物学和蛋白质化学的董事，负责改善和扩大其核心Fc receptor-mediated的药物输送技术。在加入Syntonix之前，他担任Millennium Pharmaceuticals细胞和分子生物学的高级董事。1999年，通过LeukoSite的收购，他担任相同职位。在被LeukoSite收购之前，从1994年到1999年，他在ProScript公司担任一些职位。在ProScript，LeukoSite and Millennium公司工作期间，他参与Velcade bortezomib的研发，一种癌症治疗的蛋白酶体抑制剂。他还管理其他多个项目，包括研究NF-kB的监管。他拥有罗格斯大学的微生物学学士学位和纽约大学医学中心病毒性肿瘤学和免疫学的硕士和博士学位。他还是哈佛大学Tom Maniatis。博士实验室的博士后研究员。
- Vito J. Palombella has served as our Chief Scientific Officer since January 2016. Prior to Surface, Dr. Palombella served in a variety of roles at Infinity Pharmaceuticals, Inc. from January 2004 to January 2016 most recently as Chief Scientific Officer. Prior to that, he was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Inc. now Biogen Inc. from October 2000 to January 2004 Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Co. Ltd.) from December 1999 to October 2000 Senior Director of Cell and Molecular Biology at LeukoSite, Inc. from July 1999 to December 1999 and held a number of positions at ProScript, Inc. from September 1994 to July 1999. Dr. Palombella currently serves on the Board of Directors of Molecular Partners AG. Dr. Palombella received a B.S. in Microbiology from Rutgers University and an M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center and completed his post-doctoral training at Harvard University.